Last reviewed · How we verify
Azurene (BROMPERIDOL)
Azurene works by binding to the Sigma non-opioid intracellular receptor 1, which is involved in various cellular processes.
Azurene (Bromperidol) is a small molecule drug that targets the Sigma non-opioid intracellular receptor 1. It belongs to the bromperidol class and is used to treat various conditions, although its approved indications are unknown. The commercial status of Azurene is unclear, and it is not known whether it is patented or available as a generic medication. Key safety considerations for Azurene are not well-documented. Further research is needed to fully understand its pharmacological properties and potential risks.
At a glance
| Generic name | BROMPERIDOL |
|---|---|
| Drug class | bromperidol |
| Target | D(4) dopamine receptor, Alpha-1A adrenergic receptor, D(1A) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | discontinued |
Mechanism of action
Think of it like a key fitting into a lock. Azurene is the key that binds to the Sigma receptor, which helps regulate how cells respond to certain signals. This can affect various bodily functions, such as pain perception and mood regulation.
Approved indications
Common side effects
Key clinical trials
- Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
- Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (PHASE4)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |